CancerWorld shared a post on LinkedIn:
“A cancer patient given no options left… walks into the hospital alive and thriving—48 weeks after a single treatment… Radiologic, clinical, and biochemical markers confirmed complete remission.
That’s not a plot twist from a medical drama. It’s real. And it’s the work of Dr. Jennifer S. Buell, CEO of MiNK Therapeutics.
Dr. Buell and her team have harnessed a rare type of immune cell, iNKT cells, to create an off-the-shelf therapy that can be shipped anywhere in the world.
- No patient-specific matching.
- No high-toxicity conditioning.
- No lymphodepletion.
Just immune restoration at a scale and accessibility the world has never seen before.
Why this matters:
- Treats solid tumors—not just blood cancers
- Minimal side effects, maximum immune power
- Democratizes access to advanced cell therapy
And it all started with a children’s book about Louis Pasteur, a childhood battle with meningitis, and a belief that science could—and should—save lives everywhere.
Read the full CancerWorld cover story.”
More posts featuring CancerWorld.